Users of GLP-1 drugs in the US cut their grocery spending by an average of 5.5% in the six months after taking the medication, a study shows.

Benefits advisors today are navigating a complex pharmacy benefits market with many opaque practices and hidden pitfalls.

Joey Gonzalez, global co-CEO of Barry’s, joins CNBC to discuss outlooks on fitness in the era of GLP-1 drugs, trends in gym membership, and more.

Ozempic was originally approved to treat people with Type 2 diabetes, but demand has surged because of the drug’s weight-loss ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

Which biotechs are most likely to be acquired near-term? We asked Seeking Alpha analysts Edmund Ingham and Terry Chrisomalis for their thoughts on the topic. Read more here.

"If we start seeing lots of cases outside of agricultural workers, we should be really concerned." -- James Lawler, MD, MPH, ...

As the sale of weight loss drugs skyrocket around the country, Illinois’ attorney general is saying buyer beware.

Food manufacturers are trying to whip themselves up a forkful of the slimming trend — but nutrition experts aren't giving ...

A medical spa in Lincoln Park could be the perfect getaway for those looking for nonsurgical aesthetic treatments. Shot Bar ...